The oncologic involvement of the spinal cord in neurofibromatosis type 1 (NF1) is not a typical feature of the disease. Here, we present a case of ganglioglioma of the spinal cord in a child with NF1 and try to define if this tumor can be considered coincidental or not. A 4-year-old boy affected by NF1 was diagnosed with a spinal cord-enhancing tumor extending from C4 to D3, with a disappearance in the T2 MRI sequences of the cerebrospinal fluid signal. The patient underwent a subtotal resection. The pathological exam revealed a ganglioglioma. To the best of our knowledge, only 1 other case of spinal cord ganglioglioma has been described in an NF1 patient. We suggest considering ganglioglioma in the differential diagnosis of an NF1 patient with a spinal cord tumor due to its favorable survival rate, especially in relation to the anatomical and surgical issues of this tumor that do not always entail a gross total resection.

Keywords:
Neurofibromatosis type 1, Spinal cord tumors, Ganglioglioma
1.
Huson SM, Hughes RAC (eds): The Neurofibromatoses: A Pathogenetic and Clinical Overview. London, Chapman and Hall, 1994.
2.
Marchuk DA, Collins FS: Molecular genetics of neurofibromatosis 1; in Huson SM, Hughes RAC (eds): The Neurofibromatoses: A Pathogenetic and Clinical Overview. London, Chapman and Hall, 1994, pp 23-49.
3.
Rodriguez FJ, Perry A, Gutmann DH, O'Neill BP, Leonard J, Bryant S, Giannini C: Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J Neuropathol Exp Neurol 2008;67:240-249.
4.
Listernick R, Ferner RE, Liu GT, Gutmann DH: Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 2007;61:189-198.
5.
Johannsson JH, Rekate HL, Roessmann U: Gangliogliomas: pathological and clinical correlation. J Neurosurg 1981;54:58-63.
6.
Jallo GI, Freed D, Epstein FJ: Spinal cord gangliogliomas: a review of 56 patients. J Neurooncol 2004;68:71-77.
7.
Costa J, Ruivo J, Miguéns J, Pimentel J: Ganglioglioma of conus medullaris. Acta Neurochir (Wien) 2006;148:977-980.
8.
Hayashi Y, Nakada M, Mohri M, Murakami H, Kawahara N, Hamada J: Ganglioglioma of the thoracolumbar spinal cord in a patient with neurofibromatosis type 1: a case report and literature review. Pediatr Neurosurg 2011;47:210-213.
9.
Louis DN, Ohgaki H, Wiestler OD, Cavanee WK: The WHO classification of tumours of the nervous system. Acta Neuropathol 2007;114:97-109.
10.
Rubin JB, Gutmann DH: Neurofibromatosis type 1 - a model for nervous system tumour formation? Nat Rev Cancer 2005;5:557-564.
11.
Gutmann DH, James CD, Poyhonen M, Louis DN, Ferner R, Guha A, Hariharan S, Viskochil D, Perry A: Molecular analysis of astrocytomas presenting after age 10 in individuals with NF1. Neurology 2003;61:1397-1400.
12.
Mautner VF, Asuagbor FA, Dombi E, Fünsterer C, Kluwe L, Wenzel R, Widemann BC, Friedman JM: Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Neuro Oncol 2008;10:593-598.
13.
Parizel PM, Martin JJ, Van Vyve M, van den Hauwe L, De Schepper AM: Cerebral ganglioglioma and neurofibromatosis type I. Case report and review of the literature. Neuroradiology 1991;33:357-359.
14.
Lellouch-Tubiana A, Bourgeois M, Vekemans M, Robain O: Dysembryoplastic neuroepithelial tumours in two children with neurofibromatosis type 1. Acta Neuropathol 1995;90:319-322.
15.
Fedi M, Anne Mitchell L, Kalnins RM, Gutmann DH, Perry A, Newton M, Brodtmann A, Berkovic SF: Glioneuronal tumours in neurofibromatosis type 1: MRI-pathological study. J Clin Neurosci 2004;11:745-747.
16.
Hamburger C, Büttner A, Weis S: Ganglioglioma of the spinal cord: report of two rare cases and review of the literature. Neurosurgery 1997;41:1410-1415, discussion 1415-1416.
17.
Amini A, Chin SS, Schmit MH: Malignant transformation of conus medullaris ganglioma: case report. J Neurooncol 2007;82:313-315.
18.
Haddad SF, Moore SA, Menezes AH, VanGilder JC: Ganglioglioma: 13 years of experience. Neurosurgery 1992;31:171-178.
19.
Perry A, Roth KA, Banerjee R, Fuller CE, Gutmann DH: NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumours. Am J Pathol 2001;159:57-61.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.